ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective
positive allosteric modulator
In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimuli. Some of them, like benzodiazepines or alcohol, function as psychoactive drugs. The site that ...
of the
mGlu2 receptor.
It is being studied by
Addex Therapeutics and
Janssen Pharmaceuticals
Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals) is a Belgian pharmaceutical company headquartered in Beerse, Belgium, and wholly owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.
In 1961, Janssen Ph ...
for the treatment of
schizophrenia
Schizophrenia () is a mental disorder characterized variously by hallucinations (typically, Auditory hallucination#Schizophrenia, hearing voices), delusions, thought disorder, disorganized thinking and behavior, and Reduced affect display, f ...
.
It was also researched by these companies for the treatment of
anxious depression (
major depressive disorder
Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive depression (mood), low mood, low self-esteem, and anhedonia, loss of interest or pleasure in normally ...
with
anxiety
Anxiety is an emotion characterised by an unpleasant state of inner wikt:turmoil, turmoil and includes feelings of dread over Anticipation, anticipated events. Anxiety is different from fear in that fear is defined as the emotional response ...
symptoms),
but although some efficacy was observed in
clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
s, it was not enough to warrant further development for this indication.
, ADX-71149 is in
phase II clinical trials for
schizophrenia
Schizophrenia () is a mental disorder characterized variously by hallucinations (typically, Auditory hallucination#Schizophrenia, hearing voices), delusions, thought disorder, disorganized thinking and behavior, and Reduced affect display, f ...
.
[
]
See also
* Biphenylindanone A
Biphenylindanone A (BINA, LS-193,571) is a research agent which acts as a potent and selective positive allosteric modulator for the group II metabotropic glutamate receptor subtype mGluR2.
In animal studies it showed anxiolytic and antipsych ...
* Eglumegad
* LY-404,039
* LY-379,268
* LY-487,379
LY-487,379 is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It is used to study the structure and function of this receptor subtype, and ...
References
External links
ADX71149 for Schizophrenia - Addex Therapeutics
ADX71149 for Anxiety - Addex Therapeutics
ADX 71149 - AdisInsight
4-Phenylpiperidines
Lactams
MGlu5 receptor antagonists
Chloroarenes
2-Pyridones
Experimental drugs developed for schizophrenia
Positive allosteric modulators
{{nervous-system-drug-stub